Biologics dose escalation for the treatment of inflammatory bowel disease a review of clinical effectiveness, cost-effectiveness, and guidelines
Up to one-third of inflammatory bowel disease (IBD) patients can experience that biologics become less effective and fail to maintain disease remission. In these cases, dose intensification or more frequent dosing have been considered and tried. However, the safety profile of intensified dosing and...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
CADTH
2018, August 28, 2018
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references